These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16341094)

  • 1. Herceptin: HERalding a new era in breast cancer care but at what cost?
    Hutchinson L; DeVita VT
    Nat Clin Pract Oncol; 2005 Dec; 2(12):595. PubMed ID: 16341094
    [No Abstract]   [Full Text] [Related]  

  • 2. Women with early breast cancer to be tested for trastuzumab treatment.
    Mayor S
    BMJ; 2005 Oct; 331(7521):864. PubMed ID: 16223812
    [No Abstract]   [Full Text] [Related]  

  • 3. Sucked into the Herceptin maelstrom.
    Keidan J
    BMJ; 2007 Jan; 334(7583):18. PubMed ID: 17204797
    [No Abstract]   [Full Text] [Related]  

  • 4. Breast Cancer Advocacy Coalition responds to the 'Herceptin or deception' article.
    ; Burgess EP
    N Z Med J; 2006 Jul; 119(1237):U2065; author reply U2065. PubMed ID: 16862207
    [No Abstract]   [Full Text] [Related]  

  • 5. Herceptin and early breast cancer: a moment for caution.
    Lancet; 2005 Nov; 366(9498):1673. PubMed ID: 16291043
    [No Abstract]   [Full Text] [Related]  

  • 6. Trastuzumab for early breast cancer.
    Smith IE
    Lancet; 2006 Jan; 367(9505):107. PubMed ID: 16413866
    [No Abstract]   [Full Text] [Related]  

  • 7. Adjuvant trastuzumab for breast cancer: advent of pharmacogenetics raises many issues.
    Thornton H
    BMJ; 2005 Nov; 331(7526):1202. PubMed ID: 16293848
    [No Abstract]   [Full Text] [Related]  

  • 8. PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception?
    Rosevear M
    N Z Med J; 2006 Jun; 119(1235):U2014. PubMed ID: 16751832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls.
    Brandes AA; Franceschi E; Tosoni A; Degli Esposti R
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):179-84. PubMed ID: 20131994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A "bureausceptic" view of cancer drug rationing.
    Crown J
    Lancet; 2001 Nov; 358(9294):1660. PubMed ID: 11728537
    [No Abstract]   [Full Text] [Related]  

  • 11. Final guidance issued on Herceptin after appeal rejected.
    White C
    BMJ; 2006 Aug; 333(7565):409. PubMed ID: 16931830
    [No Abstract]   [Full Text] [Related]  

  • 12. How much will Herceptin really cost?
    Barrett A; Roques T; Small M; Smith RD
    BMJ; 2006 Nov; 333(7578):1118-20. PubMed ID: 17124225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. British clinic is allowed to deny medicine; decision on cost has broad impact.
    Lyall S
    N Y Times Web; 2006 Feb; ():A10. PubMed ID: 16514743
    [No Abstract]   [Full Text] [Related]  

  • 14. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab for early breast cancer: evolution or revolution?
    Littlejohns P
    Lancet Oncol; 2006 Jan; 7(1):22-3. PubMed ID: 16408378
    [No Abstract]   [Full Text] [Related]  

  • 16. Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities.
    Van Vlaenderen I; Canon JL; Cocquyt V; Jerusalem G; Machiels JP; Neven P; Nechelput M; Delabaye I; Gyldmark M; Annemans L
    Acta Clin Belg; 2009; 64(2):100-12. PubMed ID: 19432022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimising the Role of Herceptin in Breast Cancer. Symposium proceedings. Monte Carlo, June 19-21, 2000.
    Oncology; 2001; 61 Suppl 2():1-91. PubMed ID: 11758500
    [No Abstract]   [Full Text] [Related]  

  • 18. The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapy.
    Fox KF
    Br J Cancer; 2006 Nov; 95(10):1454. PubMed ID: 17060943
    [No Abstract]   [Full Text] [Related]  

  • 19. Controversies in the use of adjuvant trastuzumab (Herceptin).
    Chowdhury S; Pickering L; Ellis P
    J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proceedings of the University of Texas M. D. Anderson Cancer Center Medical Oncologist Consensus Conference. Future Directions with Herceptin (Trastuzumab) for Breast Cancer. Maui, Hawaii, USA. July 16-18, 1998.
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):1-123; quiz 124-33. PubMed ID: 10498538
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.